The Oncology Journal Club Episode 49: ESMO 2021 Early Bird Practice Changers
Welcome to our first ESMO 2021 Special Episode. Today’s episode is focused on early bird practice changing data.
We cover KEYNOTE-716, both the breast and lung DESTINY studies, ZENITH20, TULIP, KEYNOTE-826, COVID and much more.
So join us to digest the key ESMO updates with Eva Segelov, Craig Underhill and Hans Prenen. We hope you have a few laughs too.
We hope you enjoy listening… drop us a line on Twitter with any comments @oncologynewsaus
This Week’s Papers:
1. Luke JJ et al. Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial. ESMO Congress 2021, Abstract LBA3. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741. Access online here.
2. Cortés J, et al. Trastuzumab deruxtecan (T-DXd) vs Trastuzumab =emtansine (T-DM1) in patients with HER2+ metastatic breast cancer: Results of the randomized phase III DESTINY-Breast03 study. ESMO Congress 2021, Abstract LBA1. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741. Access online here.
3. Li BT, Smit EFF,Goto Y, et al. Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC). ESMO Congress 2021, Abstract LBA45. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741. Access online here.
Alternate: Li, B.T., et al. Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer. . N Engl J Med September 18, 2021. DOI: 10.1056/NEJMoa2112431. Access online here.
4. Cornelissen R, et al. Efficacy and safety of poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations: a multinational phase II study (ZENITH20-4). ESMO Congress 2021, Abstract LBA46. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741. Access online here.
5. Saura Manich, C, et al. Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. ESMO Congress 2021, Abstract LBA15. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741. Access online here.
This Week’s Quick Bites:
1. Colombo N et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: randomized, double-blind, phase 3 KEYNOTE-826 study. ESMO Congress 2021, Abstract LBA2. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741. Access online here.
2. Conquering Cancer: Official Trailer for forthcoming documentary featuring Professor Ian Frazer AC.
3. Girard, N. et al. PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. ESMO Congress 2021, Abstract 1171MO. Annals of Oncology (2021) 32 (suppl_5): S939-S948. 10.1016/annonc/annonc728. Access online here.
4. Shen, L. et al. Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study. ESMO Congress 2021, Abstract LBA52. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741. Access online here.
5. Xu, J. et al. Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study. ESMO Congress 2021, Abstract LBA53. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741. Access online here.
6. Van Cutsem, E. et al. Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. ESMO Congress 2021, Abstract LBA55. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741. Access online here.
7. Felip, E. et al. IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC. ESMO Congress 2021, Abstract LBA9. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741. Access online here.
Alternate: Felip, Enriqueta et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. The Lancet, September 20, 2021. Access online here.
Additional Resource:
Video: #ESMO21 HIGHLIGHTS ON PATTERNS OF RELAPSE IN NSCLC TO ATEZOLIZUMAB VS BSC AFTER ADJ CT: IMPOWER010
8. Cortellini, A, et al. Prevalence and impact of COVID-19 sequelae on treatment pathways and survival of cancer patients who recovered from SARS-CoV-2 infection. ESMO Congress 2021, 1560O_PR. Annals of Oncology (2021) 32 (suppl_5): S1129-S1163. 10.1016/annonc/annonc713. Access online here.
9. Oosting, S. et al. Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors. ESMO Congress 2021, Abstract LBA8. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741. Access online here.
10. Shepherd, S. et al. Adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients: The CAPTURE study. ESMO Congress 2021, Abstract 1557O. Annals of Oncology (2021) 32 (suppl_5): S1129-S1163. 10.1016/annonc/annonc713. Access online here.
11. Information on the SerOzNET Study: First Australian clinical trial to study COVID-19 vaccines in patients with all cancers, Oncology News Australia, 1 July 2021.
Twitter Mentions:
This Week’s Team:
Professor Eva Segelov
Eva Segelov
Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.
Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.
You can find Eva on Twitter here: @profevasegelov
Professor Hans Prenen
Hans Prenen
Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings. His interests are clinical trials and translational research with a focus on digestive oncology.
You can find Hans on Twitter here: @HPrenen
Dr Craig Underhill
Craig Underhill
Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.
In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.
Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.
Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.
You can find Craig on Twitter here: @CraigUnderhill
Rachael Babin
Rachael Babin is Editor-in-Chief of The Oncology Newsletter, Publisher of Oncology News Host of The Oncology Podcast and Producer of The Oncology Journal Club. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.
With thanks to Eva Segelov, Craig Underhill, Hans Prenen and Graham Knowles.
Connect with us on Twitter @OncologyNewsAus
